Cardiovascular risk in type 2 diabetes patients
Cardiovascular diseases remain leading cause of high mortality in diabetes patients. The article is focused on the influence of diabetes on cardiovascular risks. The prevalence presented, as the significance of the main and additional risk factors of cardiovascular diseases in the development of mac...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
«SILICEA-POLIGRAF» LLC
2018-08-01
|
| Series: | Кардиоваскулярная терапия и профилактика |
| Subjects: | |
| Online Access: | https://cardiovascular.elpub.ru/jour/article/view/848 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849699000274386944 |
|---|---|
| author | O. D. Ostroumova I. V. Goloborodova V. М. Fomina |
| author_facet | O. D. Ostroumova I. V. Goloborodova V. М. Fomina |
| author_sort | O. D. Ostroumova |
| collection | DOAJ |
| description | Cardiovascular diseases remain leading cause of high mortality in diabetes patients. The article is focused on the influence of diabetes on cardiovascular risks. The prevalence presented, as the significance of the main and additional risk factors of cardiovascular diseases in the development of macrovascular complications in diabetes. In the context of influence on cardiovascular risks, modern glucose lowering drugs are considered, the safety and efficacy properties. Advantages of dapagliflozin underscored, the novel oral drug of new generation, with safe and prominent antidiabetic effect and ability to correct the main factors of cardiovascular risk (obesity, hypertension). |
| format | Article |
| id | doaj-art-546f5237c7a44529ae4780f200712c4d |
| institution | DOAJ |
| issn | 1728-8800 2619-0125 |
| language | Russian |
| publishDate | 2018-08-01 |
| publisher | «SILICEA-POLIGRAF» LLC |
| record_format | Article |
| series | Кардиоваскулярная терапия и профилактика |
| spelling | doaj-art-546f5237c7a44529ae4780f200712c4d2025-08-20T03:18:45Zrus«SILICEA-POLIGRAF» LLCКардиоваскулярная терапия и профилактика1728-88002619-01252018-08-01174819410.15829/1728-8800-2018-4-81-94575Cardiovascular risk in type 2 diabetes patientsO. D. Ostroumova0I. V. Goloborodova1V. М. Fomina2A. I. Evdokimov Moscow State University of Medicine and Dentistry (MSUMD); I.M. Sechenov First Moscow State Medical University of the Ministry of HealthA.I. Evdokimov Moscow State University of Medicine and Dentistry (MSUMD)A.I. Evdokimov Moscow State University of Medicine and Dentistry (MSUMD)Cardiovascular diseases remain leading cause of high mortality in diabetes patients. The article is focused on the influence of diabetes on cardiovascular risks. The prevalence presented, as the significance of the main and additional risk factors of cardiovascular diseases in the development of macrovascular complications in diabetes. In the context of influence on cardiovascular risks, modern glucose lowering drugs are considered, the safety and efficacy properties. Advantages of dapagliflozin underscored, the novel oral drug of new generation, with safe and prominent antidiabetic effect and ability to correct the main factors of cardiovascular risk (obesity, hypertension).https://cardiovascular.elpub.ru/jour/article/view/848diabetes mellituscardiovascular riskarterial hypertensiondyslipidemiaobesityanti-diabetic therapydapagliflozin |
| spellingShingle | O. D. Ostroumova I. V. Goloborodova V. М. Fomina Cardiovascular risk in type 2 diabetes patients Кардиоваскулярная терапия и профилактика diabetes mellitus cardiovascular risk arterial hypertension dyslipidemia obesity anti-diabetic therapy dapagliflozin |
| title | Cardiovascular risk in type 2 diabetes patients |
| title_full | Cardiovascular risk in type 2 diabetes patients |
| title_fullStr | Cardiovascular risk in type 2 diabetes patients |
| title_full_unstemmed | Cardiovascular risk in type 2 diabetes patients |
| title_short | Cardiovascular risk in type 2 diabetes patients |
| title_sort | cardiovascular risk in type 2 diabetes patients |
| topic | diabetes mellitus cardiovascular risk arterial hypertension dyslipidemia obesity anti-diabetic therapy dapagliflozin |
| url | https://cardiovascular.elpub.ru/jour/article/view/848 |
| work_keys_str_mv | AT odostroumova cardiovascularriskintype2diabetespatients AT ivgoloborodova cardiovascularriskintype2diabetespatients AT vmfomina cardiovascularriskintype2diabetespatients |